CHFR suppression by hypermethylation sensitizes endometrial cancer cells to paclitaxel

International Journal of Gynecological Cancer

Volumn 21, Issue 6, 2011, Pages 996-1003

  Wang, Xiaoyun ^a   Yang, Yuebo ^a   Xu, Chengfang ^a   Xiao, Lan ^a   Shen, Huimin ^a   Zhang, Xu ^a   Li, Tian ^a   Li, Xiaomao ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

CHFR; Demethylation; Endometrial cancer; Methylation; Paclitaxel

Indexed keywords

CHECKPOINT WITH FORKHEAD ASSOCIATED AND RING FINGER; PACLITAXEL; RING FINGER PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER RESISTANCE; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DNA METHYLATION; ENDOMETRIUM CANCER; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; DNA METHYLATION; DNA PRIMERS; ENDOMETRIAL NEOPLASMS; FEMALE; GENE SILENCING; HUMANS; NEOPLASM PROTEINS; PACLITAXEL; POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 83055196863     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e31821e05e8     Document Type: Article

References (24)

1. Whitcomb BP. Gynecologic malignancies. Surg Clin North Am. 2008;88:301Y317, vi. (Pubitemid 351434424)
2. Dizon DS. Treatment options for advanced endometrial carcinoma. Gynecol Oncol. 2010;117:373-381.
3. Humber CE, Tierney JF, Symonds RP et al. Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration. Ann Oncol. 2007;18:409Y420. (Pubitemid 46359618)
4. Scolnick DM, Halazonetis TD. Chfr defines a mitotic stress checkpoint that delays entry into metaphase. Nature. 2000;406:430Y435. (Pubitemid 30625565)
5. Chaturvedi P, Sudakin V, Bobiak ML et al. Chfr regulates a mitotic stress pathway through its RING-finger domain with ubiquitin ligase activity. Cancer Res. 2002;62:1797Y1801. (Pubitemid 34408505)
6. Kang HC, Kim IJ, Jang SG et al. Coding region polymorphisms in the CHFR mitotic stress checkpoint gene are associated with colorectal cancer risk. Cancer Lett. 2008;260:170Y179.
7. Kwon YE, Kim YS, Oh YM, et al. Nuclear localization of Chfr is crucial for its checkpoint function. Mol Cells. 2009;27:359Y363.
8. Hiraki M, Kitajima Y, Sato S et al. Aberrant gene methylation in the lymph nodes provides a possible marker for diagnosing micrometastasis in gastric cancer. Ann Surg Oncol. 2010;17:1177Y1186.
9. Jurkowska RZ, Jeltsch A. Silencing of gene expression by targeted DNA methylation: concepts and approaches. Methods Mol Biol. 2010;649:149-161.
10. Soutto M, Peng D, Razvi M et al. Epigenetic and genetic silencing of CHFR in esophageal adenocarcinomas. Cancer. 2010;116:4033-4042.
11. Toyota M, Suzuki H, Nishizaka T, et al. [Molecular mechanisms involved in epigenetic alterations in cancer]. Gan To Kagaku Ryoho. 2010;37:1650-1653.
12. Brandes JC, van Engeland M, Wouters KA et al. CHFR promoter hypermethylation in colon cancer correlates with the microsatellite instability phenotype. Carcinogenesis. 2005;26:1152Y1156. (Pubitemid 41214309)
13. Costa BM, Smith JS, Chen Yet al. Reversing HOXA9 oncogene activation by PI3K inhibition: epigenetic mechanism and prognostic significance in human glioblastoma. Cancer Res. 2010;70:453-462.
14. Ogi K, Toyota M, Mita H et al. Small interfering RNAYinduced CHFR silencing sensitizes oral squamous cell cancer cells to microtubule inhibitors. Cancer Biol Ther. 2005;4:773Y780. (Pubitemid 41351179)
15. Ji D, Deeds SL, Weinstein EJ. A screen of shRNAs targeting tumor suppressor genes to identify factors involved in A549 paclitaxel sensitivity. Oncol Rep. 2007;18: 1499-1505.
16. Kim JM, Cho EN, Kwon YE et al. CHFR functions as a ubiquitin ligase for HLTF to regulate its stability and functions. Biochem Biophys Res Commun. 2010;395:515-520.
17. Wang X, Tryndyak V, Apostolov EO et al. Sensitivity of human prostate cancer cells to chemotherapeutic drugs depends on EndoG expression regulated by promoter methylation. Cancer Lett. 2008;270:132Y143.
18. Silver DP, Richardson AL, Eklund AC et al. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol. 2010;28:1145-1153.
19. Nakamichi I, Tomita Y, Zhang B et al. Correlation between promoter hypermethylation of GSTP1 and response to chemotherapy in diffuse large B cell lymphoma. Ann Hematol. 2007;86:557Y564. (Pubitemid 47018473)
20. Nicholson LJ, Smith PR, Hiller L et al. Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer. Int J Cancer. 2009;125:1454Y1463.
21. Koga Y, Kitajima Y, Miyoshi A et al. The significance of aberrant CHFR methylation for clinical response to microtubule inhibitors in gastric cancer. J Gastroenterol. 2006;41:133Y139.
22. Privette LM, Gonzalez ME, Ding L et al. Altered expression of the early mitotic checkpoint protein, CHFR, in breast cancers: implications for tumor suppression. Cancer Res. 2007;67:6064Y6074. (Pubitemid 47037485)
23. Loring GL, Christensen KC, Gerber SA, et al. Yeast Chfr homologs retard cell cycle at G1 and G2/M via Ubc4 and Ubc13/Mms2-dependent ubiquitination. Cell Cycle. 2008;7:96Y105.
24. Fu Z, Regan K, Zhang L et al. Deficiencies in Chfr and Mlh1 synergistically enhance tumor susceptibility in mice. J Clin Invest. 2009;119:2714Y2724.